As of 2026-03-13, the Intrinsic Value of ImmuPharma PLC (IMM.L) is -7.96 GBP. This IMM.L valuation is based on the model Peter Lynch Fair Value. With the current market price of 6.64 GBP, the upside of ImmuPharma PLC is -219.89%.
Based on its market price of 6.64 GBP and our intrinsic valuation, ImmuPharma PLC (IMM.L) is overvalued by 219.89%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -7.96 - -7.96 | -7.96 | -219.89% |
| P/E | (6.64) - (8.42) | (7.93) | -219.4% |
| DDM - Stable | (4.45) - (13.63) | (9.04) | -236.1% |
| DDM - Multi | (2.47) - (6.08) | (3.53) | -153.2% |
| Market Cap (mil) | 39.72 |
| Beta | 1.71 |
| Outstanding shares (mil) | 5.98 |
| Enterprise Value (mil) | 39.33 |
| Market risk premium | 5.98% |
| Cost of Equity | 11.35% |
| Cost of Debt | 5.00% |
| WACC | 7.90% |